Please login to the form below

Not currently logged in
Email:
Password:

Spain to delay €5.4bn in unpaid drug bills

Farmaindustria, the trade body for Spain's pharmaceutical industry, is in talks with Spanish authorities to defer payment of €5.4bn owed to its members

Farmaindustria, the trade body for Spain's pharmaceutical industry, is in talks with Spanish authorities to defer payment of €5.4bn owed to its members by the country's regional governments.

According to a report in Bloomberg, Humberto Arnes, director general of Farmaindustria, said the group is negotiating on a plan to sell state-guaranteed securities backed by the unpaid bills, with proceeds going towards pharmaceutical companies.

He said: "The mechanism allows a delay until Spain is in a financial and economic situation that allows it to face the pharmaceutical bill."

Work on the proposal was at a very advanced stage, according to Arnes, with plans to have a system in place that could defer payment for four to six years and include future unpaid bills.

Spain's current drugs debt stands at €5.4bn, up from €5.19bn in March, 2011, with payment of bills delayed an average of 430 days.

In August, 2011, Spain passed a law enforcing the prescribing and dispensing of generic drugs rather than the more expensive brands, in an attempt to save €2.4bn a year and reduce the country's deficit.

Find out more about the pharmaceutical industry in Spain in PMGroup's Focus on Spain.

5th October 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...